A Phase 1 interventional study of UCART123 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), sponsored by Cellectis S.A.. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-07-31.
Sponsored by Cellectis S.A. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States — 8 open to participants now, 13 under way, none of them phase 3. Blastic Plasmacytoid Dendritic Cell Neoplasm · United States.
Among the 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States, this one is the 30th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2017, is one of 15 in phase 1, and was the 12th registered.
45 studies on the registry are indexed under Blastic Plasmacytoid Dendritic Cell Neoplasm; 14 are open to participants now.
Browse Blastic Plasmacytoid Dendritic Cell Neoplasm studies →8 of the 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 6 mo–65 yrs
Therapeutic Advances in Childhood Leukemia Consortium · Sites in United States, Australia
Ages 1–21
Immune Oncology Research Institute · Sites in United States, Armenia, Canada and 12 more countries
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Blastic Plasmacytoid Dendritic Cell Neoplasm studies recruiting now, 7 (54%) set no upper age limit and 6 (46%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 14
First in 2000; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 40 across 37 interventional studies indexed under Blastic Plasmacytoid Dendritic Cell Neoplasm.
Median enrollment 45 across the 31 interventional studies, 102 across the 2 observational. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 33 have an industry lead sponsor. The 10 most frequent:
Cellectis S.A. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Cellectis S.A. has 1 study filed under Blastic Plasmacytoid Dendritic Cell Neoplasm — fewer than ten, so there is no comparison to draw.
4 of the studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05362773MacroGenicsA Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | 2026-11 |
| NCT04216524M.D. Anderson Cancer CenterVenetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | 2026-12-31 |
| NCT02159495City of Hope Medical CenterGenetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | 2027-07-14 |
| NCT03779854Fred Hutchinson Cancer CenterNaive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 33 studies in Blastic Plasmacytoid Dendritic Cell Neoplasm with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 1 dose-finding study of Universal Chimeric Antigen Receptor T-cells targeting cluster of differentiation (CD) 123 (UCART123) administered intravenously to patients with relapsed or refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), followed by a dose expansion phase in relapsed or refractory BPDCN patients or newly diagnosed BPDCN patients.
Main Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10\^5 cells/kg to 6.25 x 10\^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.
Biological: UCART123
A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.
Biological: UCART123
Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
Incidence, nature, and severity of adverse events and serious adverse events
Time frame: Through day 84
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2017 to primary completion in Jun 2019, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Blastic Plasmacytoid Dendritic Cell Neoplasm →
Cellectis S.A.